Abstract：
Sclerostin is the protein product of the SOST gene and is known for its inhibitory effects on bone formation. The monoclonal antibody against sclerostin has been approved as a novel treatment method for osteoporosis. Oral health is one of the essential aspects of general human health. Hereditary bone dysplasia syndrome caused by sclerostin deficiency is often accompanied by some dental malformations, inspiring the therapeutic exploration of sclerostin in the oral and dental fields. Recent studies have found that sclerostin is expressed in several functional cell types in oral tissues, and the expression level of sclerostin is altered in pathological conditions. Sclerostin not only exerts similar negative outcomes on the formation of alveolar bone and bone-like tissues, including dentin and cementum, but also participates in the development of oral inflammatory diseases such as periodontitis, pulpitis, and peri-implantitis. This review aims to highlight related research progress of sclerostin in oral cavity, propose necessary further research in this field, and discuss its potential as a therapeutic target for dental indications and regenerative dentistry.
摘要：
硬骨素是SOST基因的蛋白质产物，以其对骨形成的抑制作用而闻名。抗硬化蛋白的单克隆抗体已被批准为骨质疏松症的新型治疗方法。口腔健康是一般人类健康的重要方面之一。由硬化蛋白缺乏引起的遗传性骨发育不良综合征常伴有一些牙齿畸形，激发硬化素在口腔和牙科领域的治疗探索。最近的研究发现，硬化蛋白在口腔组织中的几种功能细胞类型中表达，硬化蛋白的表达水平在病理条件下发生改变。硬化蛋白不仅对牙槽骨和骨样组织的形成产生类似的负面结果，包括牙本质和牙骨质,但也参与口腔炎症性疾病如牙周炎的发展，牙髓炎,和种植体周围炎.本文就硬化素在口腔中的相关研究进展作一综述。提出在这一领域必要的进一步研究，并讨论其作为牙科适应症和再生牙科治疗目标的潜力。
